Sequence information


DRAVP ID  DRAVPc002

Name   Boceprevir

Sequence  Not available

Molecular Formula  C27H45N5O5

Condition/Disease  Chronic HCV infection

Group  Approved, Withdrawn

Type  Peptidomimetic

Description  Boceprevir is a hepatitis C virus NS3/4A protease inhibitor used in combination with other medications to treat chronic hepatitis C genotype 1 infection. Initially approved for use in 2012, it was withdrawn in 2015 because of the availability of more effective and better tolerated all oral regimens of direct acting antiviral agents. Boceprevir is available as a fixed dose product (tradename Victrelis) used for the treatment of chronic Hepatitis C. Approved in May 2011 by the FDA, Victrelis is indicated for the treatment of HCV genotype 1 in combination with Ribavirin, Peginterferon alfa-2a, and Peginterferon alfa-2b.

Active sequence/Structure 


External Links


DrugBank Accession Number  DB08873

Pubchem ID  10324367

CHEMBL ID  CHEMBL218394

UNII  89BT58KELH

CAS  394730-60-0

Reference  22975763  22506260 



ClinicalTrails Information


NCT Number Study Title Condition/Disease Status Phase Sponsor
NCT01335529 Boceprevir in HIV-HCV Coinfected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (BocepreVIH) HCV Coinfection / Human Immunodeficiency Virus Type 1 (HIV-1) Infection Completed Phase 2 ANRS, Emerging Infectious Diseases
NCT01457937 Boceprevir/PegIFN α-2b/Riba in HCV+ Gt1 Menopausal Women, Nonresponders to PegIFN/Riba or Treatment-naives (MEN_BOC) (MEN_BOC) Chronic Hepatitis C Virus (HCV) Infection / Menopause Unknown Phase 3 University of Modena and Reggio Emilia
NCT01731301 A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD) Chronic Hepatitis C Virus (HCV) Infection / End Stage Renal Diseases Unknown Phase 4 Liver Institute of Virginia
NCT01403181 Effect of Boceprevir on HCV-specific T Cell Responses (Boce-Par) Chronic Hepatitis C Virus (HCV) Infection Completed Not available Azienda Ospedaliero-Universitaria di Parma
NCT01663922 Boceprevir and Ucalm (St John&Apos;s Wort) Hepatitis C Virus (HCV) Infection Completed Phase 1 St Stephens Aids Trust
NCT01653236 Boceprevir With Peginterferon Alfa-2b and Ribavirin in the Treatment-naive Patients Infected With Genotype 4 Chronic Hepatitis C Infection Genotype 4 Chronic Hepatitis C Infection Unknown Phase 3 Theodor Bilharz Research Institute
NCT01465516 Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir Hepatitis C Virus (HCV) Infection Terminated (The study was terminated and recruitment was capped because of the new changes in hepati Not available Arrowhead Regional Medical Center
NCT01718301 HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin (BOC-HIV) Co-Infection / Hepatitis C Virus (HCV) Infection / Human Immunodeficiency Virus (HIV) Infections Completed Phase 3 Anna Cruceta
NCT01443923 Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV Hepatitis / Human Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS) Terminated (Unable to complete enrollment due to newly approved treatment options.) Phase 4 National Institute of Allergy and Infectious Diseases (NIAID)
NCT01641666 Safety and Tolerability of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for the Treatment of Vietnamese Subjects With Chronic Hepatitis C Genotype 1 (P08599) Chronic Hepatitis C Virus (HCV) Infection Withdrawn Phase 3 Merck Sharp & Dohme LLC
NCT01585584 Triple-Therapy in Patients With HCV Genotype 3 Who Previously Failed Treatment (LeeG3) Hepatitis C Virus (HCV) Infection Completed Phase 3 University of Calgary
NCT02112630 Boceprevir in End Stage Renal Disease (ESRD) Hepatitis C Virus (HCV) Infection/End Stage Renal Disease Withdrawn (Poor enrollment) Not Applicable Columbia University
NCT02204475 Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066) Hepatitis C Virus (HCV) Infection Withdrawn Phase 3 Merck Sharp & Dohme LLC
NCT00160251 Boceprevir (SCH 503034) Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Riba Chronic Hepatitis C Virus (HCV) Infection Completed Phase 2 Merck Sharp & Dohme LLC
NCT01912495 Dutch Acute HCV in HIV Study (DAHHS) (DAHHS) Hepatitis C Virus (HCV) Infection / Human Immunodeficiency Virus (HIV) Infections Completed Phase 2 Erasmus Medical Center
NCT01482403 A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis CA Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients Wi Chronic Hepatitis C Virus (HCV) Infection Completed Phase 2 Hoffmann-La Roche
NCT01591460 A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C Virus (HCV) Infection Completed Phase 4 Hoffmann-La Roche
NCT02118597 An Observational Study Examining the Use of Triple Combination Therapy With Boceprevir, Peginterferon Alfa-2a and Ribavirin in the Re-Treatment of Chronic Hepatitis C Patients Chronic Hepatitis C Virus (HCV) Infection Terminated (Study terminated due to the Sponsor's decision.) Not available Hoffmann-La Roche
NCT01446250 Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1 Hepatitis C Virus (HCV) Infection Terminated Phase 3 Debiopharm International SA
NCT01463956 Efficacy of PegInterferon-Ribavirin-Boceprevir Therapy in Patients Infected With G1 HCV With Cirrhosis, Awaiting Liver Transplantation Hepatitis C Virus (HCV) Infection / Liver Cirrhosis, Experimental Completed Phase 2 French National Agency for Research on AIDS and Viral Hepatitis
NCT02113631 Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir Chronic Hepatitis C Virus (HCV) Infection /Cirrhosis Completed Not applicable Louis Stokes VA Medical Center
NCT01925183 Individualized Triple-therapy Using Boceprevir in HIV-positive Patients With Hepatitis C (HIVCOBOC-RGT) Chronic Hepatitis C Virus (HCV) Infection / Human Immunodeficiency Virus (HIV) Infections Completed Phase 4 Markus Peck-Radosavljevic
NCT01770223 A Study of Viral Response to Triple Therapy in Hepatitis C Virus-Infected Participants With Insulin Resistance Who Failed Dual Therapy (MK-3034-113) Hepatitis C Virus (HCV) Infection Withdrawn Phase 4 Merck Sharp & Dohme LLC
NCT01447446 An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C Chronic Hepatitis C Virus (HCV) Infection Completed Not available Hoffmann-La Roche
NCT00423670 Safety and Efficacy of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03523) Chronic Hepatitis C Virus (HCV) Infection Completed Phase 2 Merck Sharp & Dohme LLC
NCT01396005 A Study to Evaluate the Pharmacokinetic Effect of SCH 503034 (Boceprevir) on Methadone or Buprenorphine/Naloxone Plasma Concentrations (P08123) Hepatitis C Virus (HCV) Infection Completed Phase 1 Merck Sharp & Dohme LLC
NCT01181804 Comparison of Safety and Resulting Blood Level Profiles After Administration of a New Boceprevir Tablet Versus Its Current Capsule Formulation for Treatment of Chronic Hepatitis C (P06992)(COMPLETED) Hepatitis C Virus (HCV) Infection Completed Phase 1 Merck Sharp & Dohme LLC
NCT00959699 A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4) Hepatitis C Virus (HCV) Infection / Human Immunodeficiency Virus (HIV) Infections Completed Phase 2 Merck Sharp & Dohme LLC
NCT00845065 Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05685AM2)(COMPLET Chronic Hepatitis C Virus (HCV) Infection Completed Phase 3 Merck Sharp & Dohme LLC
NCT00708500 Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED) Chronic Hepatitis C Virus (HCV) Infection Completed Phase 3 Merck Sharp & Dohme LLC
NCT02758509 Impact of Antiviral Therapy on Gastroesophageal Varices. Chronic Hepatitis C Virus (HCV) Infection Completed Not available Parc de Salut Mar
NCT00705432 Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED) (SPRINT-2) Chronic Hepatitis C Virus (HCV) Infection Completed Phase 3 Merck Sharp & Dohme LLC
NCT01945294 Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-30 Chronic Hepatitis C Virus (HCV) Infection Completed Phase 3 Merck Sharp & Dohme LLC
NCT01756079 A Study to Evaluate the Efficacy and Safety of Boceprevir Added to Standard of Care Therapy in Previously Treated Participants With Chronic Hepatitis C Genotype 1 and Cirrhosis (MK-3034-105) Hepatitis C Virus (HCV) Infection Completed Phase 4 Merck Sharp & Dohme LLC
NCT01544920 Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755) Chronic Hepatitis C Virus (HCV) Infection Completed Phase 3 Merck Sharp & Dohme LLC
NCT01425190 Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P07614) Chronic Hepatitis C Virus (HCV) Infection Terminated (The US FDA and the EU CHMP provided guidance indicating preference for intereferon-free Phase 1 Merck Sharp & Dohme LLC
NCT01390844 Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063) Chronic Hepatitis C Virus (HCV) Infection Completed Phase 3 Merck Sharp & Dohme LLC
NCT00689390 Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063) Chronic Hepatitis C Virus (HCV) Infection / Hepacivirus Terminated (The study was terminated due to satisfaction of post-marketing commitments) Phase 2,3 Merck Sharp & Dohme LLC
NCT01353911 Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003) Chronic Hepatitis C Virus (HCV) Infection Completed Phase 2 Merck Sharp & Dohme LLC
NCT01470690 Pharmacokinetic Study of the HCV Protease Inhibitor Bo-cePRevir and the Proton Pump Inhibitor OMeprazOle (PROMO) (PROMO) Gastric Acid-related Disorders / Hepatitis C Virus (HCV) Infection Completed Phase 1 Radboud University Medical Center
NCT01590225 Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P08034) Chronic Hepatitis C Virus (HCV) Infection Withdrawn Phase 3 Merck Sharp & Dohme LLC
NCT01288417 Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir (OPAL) Hepatitis C Virus (HCV) Infection/ Human Immunodeficiency Virus Infection(HIV) Completed Phase 1 Radboud University Medical Center
NCT01425203 The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160) Chronic Hepatitis C Genotype 1 Completed Phase 3 Merck Sharp & Dohme LLC
NCT01023035 Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM2) Chronic Hepatitis C Virus (HCV) Infection Completed Phase 3 Merck Sharp & Dohme LLC
NCT00910624 Boceprevir Treatment in Participants With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin (P05514) (PROVIDE) Chronic Hepatitis C Virus (HCV) Infection Completed Phase 3 Merck Sharp & Dohme LLC
NCT01482767 Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection Hepatitis C Virus (HCV) Infection / Human Immunodeficiency Virus (HIV) Infections Completed Phase 3 National Institute of Allergy and Infectious Diseases (NIAID)
NCT02333292 Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions Hepatitis C, Chronic Completed Valme University Hospital